[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones

US10167293B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Marcus Koppitz · Berlin, DE
• Holger Siebeneicher · Berlin, DE
• Holger STEUBER · Berlin, DE
• Antonius Ter Laak · Berlin, DE
• Reinhard NUBBEMEYER · Berlin, DE
• Antje ROTTMANN · Berlin, DE
• Horst IRLBACHER · Berlin, DE
• Benjamin Bader · Berlin, DE
• Michaele PETERS · Berlin, DE
• Andrea Wagenfeld · Berlin, DE
• Ildiko Terebesi · Berlin, DE

Key dates

• Filing date: May 16, 2017
• Grant date: Jan 1, 2019
• Expiry date: May 16, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.